Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Real-World Data Identify Factors Associated With Long-Term Response to Regorafenib in mCRC

January 20th 2024

Favorable ECOG PS, lower LDH levels, and absence of BRAF and KRAS mutations at baseline were associated with long-term response to regorafenib in patients with mCRC in the real world.

Dr Kasi on the Rationale for Analyzing ctDNA to Inform Chemotherapy Decisions in CRC

January 20th 2024

Pashtoon Murtaza Kasi, MD, MS, discusses outcomes from an interim analysis of the BESPOKE CRC study and highlights the use of circulating tumor DNA for informing adjuvant chemotherapy treatment decisions for patients with stage II/III colorectal cancer.

DKN-01 Plus Bevacizumab and Chemotherapy Shows Tolerability, Activity in MSS CRC

January 20th 2024

DKN-01/bevacizumab/chemotherapy had a tolerable safety profile and showcased clinical activity in patients with microsatellite stable colorectal cancer.

Neoadjuvant Botensilimab/Balstilimab Combo Induces Early Efficacy in pMMR/dMMR CRC

January 20th 2024

Neoadjuvant botensilimab/balstilimab led to robust responses in both patients with resectable mismatch repair–proficient and –deficient colorectal cancer.

Fruquintinib Plus BSC Provides Clinically Meaningful Quality-Adjusted Survival Benefit Vs BSC Alone in mCRC

January 20th 2024

An improvement in quality-adjusted survival benefit was observed with fruquintinib/BSC vs BSC alone in patients with mCRC enrolled in the FRESCO study.

FOLFOXIRI Plus Bevacizumab Use Rises Over Time in mCRC

January 20th 2024

The use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer from 2013 to 2022, especially in patients 50 years of age or younger.

Dr Imanirad on Toxicity Management for Encorafenib Plus Cetuximab in BRAF-Mutant mCRC

January 18th 2024

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

Futility Analysis Ends Nivolumab and Relatlimab Evaluation in Pretreated MSS mCRC

January 3rd 2024

The phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab in patients with microsatellite stable metastatic colorectal cancer will be discontinued due to futility.

End of Year Review in CRC: Exploring Emerging Treatment Options and Clinical Insights on the Future Landscape

December 20th 2023

Cathy Eng, M, FACP, FASCO, presents a comprehensive End-of-Year Review in Colorectal Cancer (CRC), delving into the exploration of emerging treatment options and clinical insights on the future landscape. This insightful review includes a focus on the recent approval of fruquintinib and important updates on target therapies for HER2+, BRAF V600E-Mutant, and KRAS-mutant CRC, as well as an interactive Q&A segment.

Nivolumab Plus Ipilimumab Improves PFS in Newly Diagnosed Metastatic Colorectal Cancer

December 7th 2023

The combination of nivolumab and ipilimumab led to a statistically significant and clinically meaningful improvement in progression-free survival per blinded independent central review compared with investigator’s choice of chemotherapy as frontline therapy in patients with metastatic colorectal cancer.

Sintilimab Triplet Demonstrates Efficacy With Acceptable Safety in pMMR/MSS CRC

November 30th 2023

The triplet combination of sintilimab, chidamide, and bevacizumab resulted in a high 18-week progression-free survival rate with a favorable toxicity profile in patients with microsatellite stable or mismatch repair–proficient metastatic colorectal cancer, according to data from the phase 2 CAPability-01 trial.

First-Line Pembrolizumab Demonstrates Durable Clinical Benefit in MSI-H/dMMR mCRC

November 30th 2023

Pembrolizumab continued to demonstrate at trend toward improved overall survival compared with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.

Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC

November 22nd 2023

Patrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.

SCO-101 Plus FOLFIRI Prolongs Survival in Metastatic Colorectal Cancer

November 22nd 2023

SCO-101 in combination with leucovorin, fluorouracil, and irinotecan (FOLFIRI) prolonged survival in heavily pretreated patients with metastatic colorectal cancer who had no other active treatment options available, according to final data from part 2 of the phase 2 CORIST study.

FDA Approval of Fruquintinib Expands Later-Line Treatment Options in mCRC

November 17th 2023

John Lindsay Marshall, MD, sheds light on the significance of the FDA approval of fruquintinib for patients with heavily pretreated metastatic colorectal cancer and discusses the efficacy and safety data from the FRESCO and FRESCO-2 trials that supported the decision in this population.

FDA Approves Fruquintinib for Metastatic Colorectal Cancer

November 8th 2023

The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

FDA Approves Fruquintinib for Metastatic Colorectal Cancer-Audio Test

November 8th 2023

Panitumumab Plus FOLFIRINOX or mFOLFOX6 Elicits Similar Responses in RAS/BRAF V600E Wild-Type Unresectable mCRC

November 6th 2023

The addition of panitumumab to FOLFIRINOX or mFOLFOX6 led to comparable overall response rates and complete response rates in patients with RAS or BRAF V600E wild-type, unresectable, metastatic colorectal cancer without liver-limited disease.

Garsorasib Plus Cetuximab Shows Early Efficacy in Heavily Pretreated KRAS G12C+ CRC

November 6th 2023

The combination of garsorasib and cetuximab elicited responses and was found to be well tolerated in heavily pretreated patients with KRAS G12C–mutated colorectal cancer.

Sotorasib Plus Panitumumab Extends PFS in Refractory KRAS G12C+ mCRC

October 22nd 2023

Treatment with combinations using sotorasib at multiple dose levels and panitumumab led to improved progression-free survival vs standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.